Effect of Esketamine on Depressive Symptoms of Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Esketamine, as a powerful analgesic intravenous anesthetic, has a rapid onset and elimination
effect, does not inhibit spontaneous respiration, and can slightly stimulate the circulatory
system. It has been confirmed that esketamine can effectively combat opioid related
complications, especially life-threatening respiratory suppression. Thus becoming a new
powerful perioperative analgesic drug. At the same time, esketamine has been licensed for the
treatment of "resistant depression" and emergency treatment for patients in crisis states of
depression. But the evidence for its safety and effectiveness is insufficient. We have
designed a randomized controlled clinical trial to investigate the effect of an established
general anesthesia strategy without opioids by using esketamine on postoperative depressive
in obese patients undergoing laparoscopic sleeve gastrectomy.